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Background: Standard MRI has been used for high-grade gliomas detection, albeit with limited success as it does not
provide sufficient specificity and sensitivity to detect complex tumor structure. Therefore targeted contrast agents based
on iron oxide, that shorten mostly T2 relaxation time, have been recently applied. However pulse sequences for molecular
imaging in animal models of gliomas have not been yet fully studied. The aim of this study was therefore to compare
contrast-to-noise ratio (CNR) and explain its origin using spin-echo (SE), gradient echo (GE), GE with flow compensation
(GEFC) as well as susceptibility weighted imaging (SWI) in T2 and T2* contrast-enhanced molecular MRI of glioma.
Methods: A mouse model was used. U87MGdEGFRvIII cells (U87MG), derived from a human tumor, were injected
intracerebrally. A 9.4 T MRI system was used and MR imaging was performed on the 10 day after the inoculation of
the tumor. The CNR was measured prior, 20 min, 2 hrs and 24 hrs post intravenous tail administration of glioma
targeted paramagnetic nanoparticles (NPs) using SE, SWI, GE and GEFC pulse sequences.
Results: The results showed significant differences in CNR among all pulse sequences prior injection. GEFC
provided higher CNR post contrast agent injection when compared to GE and SE. Post injection CNR was the
highest with SWI and significantly different from any other pulse sequence.
Conclusions: Molecular MR imaging using targeted contrast agents can enhance the detection of glioma cells at
9.4 T if the optimal pulse sequence is used. Hence, the use of flow compensated pulse sequences, beside SWI,
should to be considered in the molecular imaging studies.
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MRI has been widely recognized as a diagnostic tool for
early cancer detection, treatment monitoring and image
guided surgery. Of particular interest is imaging of high-
grade gliomas due to their rapid growth [1] and very poor
prognosis with a median survival rate of only 9 months [2].
Standard contrast enhanced MRI, including applica-
tion of Gd-based T1 contrast agents [3,4] do not provide
sufficiently high specificity for tumor diagnosis and thus
require targeted contrast agents which can be applied to
provide information on tumor status (e.g. [5-7]). One* Correspondence: tomanekb22@gmail.com
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reproduction in any medium, provided the orapproach to apply a molecular contrast agent which is
usually composed of a superparamagnetic core and a
shell of varying composition and size [8,9]. The
superparamagnetic core reduces T2, T2*, and to a lesser
degree, T1 relaxation times while the shell of the con-
trast agent is typically utilized to decrease toxicity and to
allow nanoparticle (NP) functionalization [10]. Further-
more, increased core size increases T2 shortening and
decreases T2/T1 ratio [11]. The small size of iron based
NPs (usually 5–20 nm) and their strong impact on T2
and T2*, even in very small concentrations, make them
ideal compounds for application to molecular imaging.
Their T2 relaxivity can be up to 20 times that of Gd-
DTPA [12].
While the impact of the size and composition of
targeted contrast agents on MR properties have beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pulse sequences for molecular imaging in animal models
of gliomas have not been yet fully characterized. The
competing requirements of molecular contrast imaging
are to minimize cytotoxicity and maximize signal detec-
tion in vivo, and thus, require application of low concen-
trations of the contrast combined with an imaging
technique that provides optimum contrast-to-noise ratio
(CNR) enabling clinical application. While optimum
pulse parameters for ex vivo experiments, when T2 and
T2* are known, are relatively easy to establish, in vivo ex-
periments are more complex as they include physio-
logical parameters such as respiration, heart rate or
blood flow that are very difficult to predict theoretically
and to include into pulse sequence parameters. While
there are methods for reducing motion artifacts, such as
gating (e.g. [13]), data post processing [14] or ordered
phase encoding [15] these methods do not address spin
dephasing between excitation pulses and data acquisition
due to fluid flows. To overcome these MR sequence
shortfalls, we applied a pulse sequence that uses flow
compensating gradients, known as gradient moment
nulling (GMN) [16-18]. The goal of our studies was to
optimize CNR using spin echo (SE), gradient echo (GE)
and gradient echo with flow compensation (GEFC) in
contrast-enhanced molecular MRI at 9.4 T. As suscepti-
bility weighted imaging (SWI) [19,20] is frequently used
for molecular MRI we also converted GE images into
SWI as reference images. An in vivo model was used for
evaluating CNR of antibody-targeted iron nanoparticles
in transplanted glioma using a range of pulse sequences
to assess the vascular density of the tumor.
Materials and methods
Tumor cell preparation
Details of the tumor and cell preparation have been pre-
viously published (e.g. [1]). Briefly, the U87MGdEGFRvIII
cell line (U87MG) was derived from a human tumor
known to express high levels of vascular endothelial
growth factor and epidermal growth factor receptor [21].
This cell line was provided by the Ludwig Institute for
Cancer Research (La Jolla, California, USA). The U87MG
implants grow as solid, nonencapsulated spheroidal tu-
mors. The tumor displays a dense vascular network, with
many of the characteristics of glioblastoma vessels [3,7]
including tortuous vessels with abnormal vascular base-
ment membranes and increased permeability.
U87MG cells were cultured in DMEM solution
supplemented with 10% fetal calf serum and maintained
in a humidified 5% CO2 atmosphere at 37°C. Cells were
harvested by trypsinization in ethylenediaminetetraacetic
acid (EDTA)/trypsin, washed in phosphate-buffered sa-
line (PBS), and centrifuged three times at 200 G. Viabil-
ity was assessed using a 0.4% trypan blue exclusion test.After cell density was determined, cells were brought
into suspension at a final concentration of 5 × 104/2.5 μL
and mixed with 2.5 μL of matrigel for a total volume of
5 μL. Cells were kept on ice until inoculation.
Tumor model
Six CD-1 nude mice (male, 6 weeks old, Charles River,
Canada) were anesthetized by intraperitoneal injection
of a mixture of ketamine (8 mg/kg) and xylazine (6 mg/
kg) and placed in a stereotactic head frame (Kopf Instru-
ments, Tujunga, CA). Tumor cells were inoculated
using procedures described previously [1,3,7]. Briefly,
the scalp was shaved and swabbed with iodine and alco-
hol. The skin was incised and a 0.18 mm diameter
hole was drilled in the skull. Approximately 5 × 104
U87MGdEGFRvIII glioma cells, suspended in a total vol-
ume of 5 μL, were injected intracerebrally into the
frontal lobe of each mouse with a chromatography syr-
inge at a depth of 2.5-3 mm (1 mm anterior and 1.8 mm
lateral to the bregma). Subsequently, the bony calvarium
was sealed by a droplet of bone wax to prevent reflux
and the skin was sutured. After the surgery, animals
were allowed to recover from the anesthesia and were
placed in their cages. All animal procedures were ap-
proved by the local Animal Care Committee.
Contrast agent synthesis and injection
Commercially available iron oxide NPs were used
(Nanotech-Ocean, USA). The NP consists of the mean
core Fe3O4 diameter of 20 nm embedded in dextran
matrix, with a hydrodynamic diameter of about 63 nm
[21-23]. The NPs were functionalized with IGFBP7-sdAb
[24,25], an antibody that binds with high specificity to
glioma vasculature. Intravenous tail injection was used
to deliver the contrast agent after the first series of MR
images was obtained.
Histology
To confirm accumulation of the contrast within the
tumor, histology was performed at the end of the experi-
ment. Mice were sacrificed by intracardiac perfusion
with heparinzed saline and their brains were excised and
fixed in formalin (Figure 1). Coronal sections (50 μm)
were obtained using a Vibratome (Ted Pella, Redding,
California). Brain tissue sections were examined for the
presence of iron nanoparticles by an Iron Stain Kit
(Sigma) as per manufacturer’s instructions. Briefly, the
sections were incubated for 30 min at room temperature
with iron staining solution (a 1:1 mixture of 4% potas-
sium ferrocyanide and 4% hydrochloric acid). Sections
were then washed in deionized water and incubated for
3 min with 1% pararosaniline solution diluted 1/50 in
water, followed by additional washing with deionized
water. Tissue sections were then mounted on Superfrost
Figure 1 Microscopic images of mouse glioma sections
obtained using Prussian Blue staining collected after the last
MRI session (24 hours after intravenous injection of the
targeted contrast agent). The image shows accumulation of the
iron within the tumor (as indicated by the black arrow). Blue spots
indicate iron, red - nuclei and pink - cytoplasm.
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Canada), cover slipped using mounting media and exam-
ined under a light microscope.
MRI protocol
The MRI sessions started 10 days after cell inoculation
when the tumor was about 2 mm in diameter. A 9.4 T/
21 cm horizontal bore magnet (Magnex, UK) with a
Biospec console (Bruker, Germany) was used. A volume
(3 cm diameter, 2.5 cm long) radio-frequency coil was
placed over the animal’s head covering the region of
interest namely frontal cortices. For in vivo MRI experi-
ments, a 2 mg Fe/ml concentration of the functionalized
contrast agent was used [26] and 200 μl of the contrast
agent was slowly (2–3 min) administered via tail vein
using a 0.5-ml insulin syringe with a 27-gauge fixed nee-
dle (vehicle, 0.9% saline).
Three pulse sequences were tested: spin echo (SE),
gradient echo (GE) and GE with flow compensation
(GEFC). The MRI session started with SE 20 min after
contrast injection (SE lasted 10 minutes) and it was
followed by GE and GEFC CNR was calculated for each
pulse sequence and eight echo times (TE) for each pulse
sequence were tested to find the TE that provided max-
imum CNR. T2- and T2*-weighted axial images were ac-
quired at the level of the tumor. FOV = 2 × 2 cm and
slice thickness of 1 mm were used for each pulse se-
quence. For 2D GE we used the following parameters:
TR = 50 ms, 10 continuous slices, 10 averages, 78 kHz
bandwidth (BW), 1 ms Hermit selective pulse with a 15
degree flip angle, echo time (TE) 3, 7, 11, 15 and 19 ms.
For 2D GEFC: TR = 50 ms, TE = 7 ms, 1 ms sin10h se-
lective pulse with a flip angle 15°, BW = 50 kHz, 2 con-
tinuous slices, 10 averages were applied. A multiecho 2DSE sequence was used with TR = 5000 ms, 1 average, 10
continuous slices, 16 echoes, 10 ms apart each, first echo
at 10 ms. Matrix size was 256 × 256 for SE and 128 ×
128 for GE and GEFC. Total data acquisition time was
10 min for SE, 1 min for GE and 1 min for GEFC.
The SW images, for both GE and GEFC data, were
processed as described by Haacke et al. [19]. The raw
time-domain data were zero filled to 512 × 512 prior to
2D Fourier transformation and a phase image generated
in the frequency domain. A high-pass filter was used to
remove the low-spatial-frequency phase as follows: the
central 48 × 48 points were used to create a phase image
which was then used to subtract out the low-frequency
phase components of the original 512 × 512 phase
image. A mask was then calculated to multiply the
512 × 512 magnitude image using the following rule
designed to enhance pixels of positive phase:
f x; yð Þ ¼ π−ϕ x; yð Þ
π
for π > ϕ x; yð Þ > 0
f x; yð Þ ¼ 1 otherwise
ð1Þ
This mask was multiplied with original magnitude
image four times to produce the final SW image.
The applied GEFC pulse sequence uses first order flow
compensation gradients in three directions. The flow
compensation gradients reduce the signal loss due to
flow. In our study TE = 7 ms was found to provide the
maximum CNR thus that value was used for all scans.
SNR and CNR were calculated as follows:
SNR tð Þ ¼ SI tð Þ
Noise
ð2Þ
CNR ¼ SI tð Þ−SI bð Þ
Noise
ð3Þ
where SI(t) and SI(b) are the averaged signal intensities
within the tumor and a normal brain region respectively;
Noise is the averaged noise outside the rodent head (in
the air) ROIs for tumor and brain were selected using
pre-contrast SE pulse sequence, as areas within the
tumor and the corresponding contralateral brain region
(see Figure 2). Due to the different bandwidths (50 kHz
vs 78 kHz) used for the GE and GEFC sequences which
would result in a SNR advantage for GEFC all SNR and






) to correct for this advantage.
Results
Several pilot experiments with different TEs for each
pulse sequence were performed to optimize CNR. The
optimum CNR was found to be TE = 7 ms for GE and
GEFC pulse sequences and TE = 60 ms for SE. Examples
of pre- and post-contrast MRIs using SE, GE and GEFC
Figure 2 A method of calculating CNR using ROIs. SI(t) and SI(b)
are the averaged signal intensities within the tumor (red line)
and a normal brain (blue line) region respectively; Noise was
measured outside the mouse head (white line). ROIs were
selected using pre-contrast SE pulse sequence.
Figure 3 MR images of the tumor bearing mouse using GE, GEFC, SE
after intravenous tail injection of targeted contrast agents: prior, 20,
GE and prior, 31, 131 min and 2 hrs for GEFC. TR/TE = 50/7 ms for GE a
Note the increased negative contrast for GE and GEFC after contrast agent
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The pulse parameters remained unchanged for each
MRI session. Pre-injection GE, GEFC and SW MR im-
ages showed very low contrast while pre-injection SE
MRI showed good contrast between tumor and healthy
brain tissues. The pre-injection CNR for each pulse se-
quence were significantly (p < 0.05) different from each
other. Following contrast agent administration, CNR in-
creased significantly for SWI, GE and GEFC pulse se-
quences, but decreased for SE. The absolute values of
CNR for GE and SE were not significantly different at
20 min after injection, however the contrast was re-
versed: tumor was darker than normal tissue in GE and
brighter in SE MRI.
CNR was higher for GEFC 310 and 131 min after in-
jection when compared to GE at 30 and 130 min, and
SE at 20 and 120 min, but it was not significantly higher
24 hrs after injection when compared to SE. The
changes in the absolute CNR values for each pulse se-
quence averaged over 6 animals are shown in Figure 4,
while the corresponding CNR values are presented in
Table 1. The contrast remained positive (tumor brighter)as well as SWI(GE) and SWI(GEFC) at the following time points
120 min and 24 hrs post for SE; prior, 30, 130 min and 24 hrs for
nd GEFC. TR/TE = 5000/60 ms for SE. FOV = 2 × 2 cm for each MRI.
injection.
Figure 4 Absolute CNR values for SE, GE, GEFC obtained prior,
20/30/31, 120/130/131 and 1440/1450/1451 min (~24 hrs) post
intravenous tail contrast injection respectively. SWI obtained
from GE and GEFC data are also shown for comparison. Note the
two-fold increase in CNR with the GEFC pulse sequence and
even larger increase for SWI after injection of the targeted NP.
(The sequence durations are not to scale for clarity.)
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GEFC at each time point.
In addition, based on multi-echo GE and single expo-
nent echo train fitting, we measured T2
* of tumor and
brain areas. T2
* within the tumor area decreased almost
two fold (from about 15 ms to about 7 ms) following in-
jection. Brain T2
* decreased by about 15% (from about
16 ms to 14 ms) in the same time. While the T2* of the
blood could not be directly measured it was estimated
based on the expected contrast agent concentration. We
injected 0.4 mg Fe into the mouse with an approximate
total blood volume of 1.9 ml resulting in an estimated
iron concentration of 3.7 mM. The R2 relaxivity of the
contrast agent is about 100 mM-1 s-1 at 9.4 T based on
other agents with a similar core and hydrodynamic size
[26]. Therefore, if the blood initially had a T2
* value ofTable 1 Comparison of CNR between the tumor and brain
regions using GEFC, GE and SE pulse sequences as well
as SWI at the respective time points: 20, 120 min and
24 hrs for SE; 30, 130 min and 24 hrs for GE; 31, 131 min
and 24 hrs for GEFC post iv tail injection of the targeted
contrast agent
Pre 20/30/31 min 120/130/131 min 24 hrs
GEFC −0.6 −8.4 −5.5 −6.1
GE 1.4 −4.3 −2.2 −2.7
SE 7.3 4.3 4.8 5.8
SWI (GE) −1.2 −15.8 −5.8 −4.4
SWI (GEFC) −1.7 −24.5 −8.4 −6.9
The negative CNR value indicates that tumor is darker than normal brain.~10 ms, just after administration of the contrast agent
the T2
* would be about 2 ms and would gradually in-
crease towards its initial value at the later time points.
There is a lack of signal from arteries in GEFC MRI
31 min after injection caused by the high concentration
of iron oxide in the blood due to the extremely short T2
* .
Such a short relaxation time overwhelms the usual time-
of-flight inflow enhancement seen in the arteries in the
other flow compensated images. The brain and tumor
signal-to-noise (SNR) before and at different time points
after injection was about 10% higher for GEFC than for
GE (Table 2) after correcting for the bandwidth differ-
ence.The SNR of the brain for SE decreased 20 min after
injection by about 20%: from 34.3 to 27.8 for brain. The
CNR (Table 1 and Figure 4) was almost twofold higher
for GEFC 31 and 131 min after injection than for GE at
30 and 131 min, and 3.7 and 5.7 times higher after injec-
tion for SWI obtained from GE and GEFC respectively
when compared to either the SE or GE sequences. The
CNR decreased about 3 times for both SWI(GE) and
SWI(GEFC) 130 min post injection and 4 times after
24 hrs yet remained about 2–3 times higher than GE or
GEFC. This demonstrates that SWI based on GEFC in-
deed provides superior CNR for glioma detection when
a targeted NP is utilized.Discussion
Early detection of glioma, when the tumor is about a
millimeter in size, may be associated with long-term sur-
vival [27,28]. However, conventional anatomical imaging
techniques based on SE providing T1 and T2-weighted
MRI typically can only detect neoplasias of several milli-
meters or larger, which contain approximately 1 million
cells. Such large tumor size greatly decreases the odds of
survival [28-31]. Furthermore, current clinical tumor
segmentation methods require a trained operator’s input
and is based on manual marking of tumor edges on T2-
weighted MRI [29,30]. Therefore, early detection of the
tumor and precise, accurate and fast determination of
the tumor position and its boundaries are of particular
clinical importance.Table 2 Comparison of SNR from the normal brain for SE,
GE and GEFC pulse sequences pre, and at the respective
time points: 20, 120 min and 24 hrs for SE; 30, 130 min
and 24 hrs for GE; 31, 131 min and 24 hrs for GEFC post
iv tail injection of the targeted contrast agent
Pre 20/30/31 min 120/130/131 min 24 hrs
SE 25.3 19.7 25.9 26.2
GE 29.0 18.7 24.5 25.4
GEFC 31.2 21.1 25.9 29.8
The standard deviation was smaller than ±1.3 for each measurement. The SNR
for GE is corrected for the bandwidth difference (0.8).
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brighter before contrast application due to longer T2
tumor values. The elevated T2 values of high-grade gli-
omas involve many processes within tumor cells and
their associated tumor blood vessels [29-32]. High-grade
glioma angiogenesis results in hypervascularization,
tortuous vessels exhibiting increased permeability,
vasogenic edema, retention of plasma fluids and proteins
within the extracellular space [1,3,7,33-37]. Furthermore,
overexpression of CXCR4, a chemokine receptor known
to mediate glioma cells invasiveness, has been correlated
with increased T2 [30]. All these factors contribute to a
longer T2 value within the tumor compared to healthy
brain tissues thus leading to tumor hyperintensity and
high positive contrast in SE T2-weighted images. This is
in contrast to GE based techniques which have very little
innate contrast. GE, GEFC and SW MR images prior to
injection of the NP in our study showed very low con-
trast between tumor and healthy brain tissues.
Application of a superparamagnetic contrast agent re-
duces T2 and T2* of both brain and tumor decreasing
their SNR. It has been previously reported that the high
intravascular blood volume and vessel leakage in glioma
causes more contrast to be delivered and accumulate in
the tumor than in the brain [3,38,39] decreasing the T2
and T2* of the tumor more than that of the brain
[40,41]. This decreases the CNR in SE sequences (which
start with positive contrast) and generates high negative
contrast in GE sequences. This observation was verified
with post-injection images demonstrating significantly
increased absolute CNR for the GE, GEFC and SW(GE)
and SW(GEFC) images (by 2.9, 7.8, 14.8 and 22.2 re-
spectively), but decreased CNR for SE (by 3.0). It should
also be noted, that acquisition time of SE is much longer
than GE-based technique which makes SE less suitable
for molecular imaging.
The best CNR was achieved with the SW images
processed from the GEFC sequence at 30 min post injec-
tion, but similar contrast was obtained at the 131 min
and 24 hour time point. This is expected as SWI is
known to be very sensitive to superparamagnetic iron
based contrast agents [19,20]. The GEFC images also
showed better contrast compared to the GE images. This
result is likely caused by at least two phenomena, that
each contributes to the overall significant differences be-
tween GE and GEFC. We partially attribute the results
to an increased SNR in the GEFC images due to the ac-
tion of the flow compensation gradients and to an in-
creased cancelation between signals from the blood and
brain tissues. The increase of SNR in GEFC depends
mostly on the efficacy of the applied compensating
gradients, namely their proper balancing. The signal
cancelation from the brain and blood should be consid-
ered in the terms of contrast agents containingsuperparamagnetic NPs that cause a local susceptibility
effect leading to a phase shift within the blood vessels
[42,43]. This phase shift can cause the signal from the
blood to cancel with the signal from the tissue at appro-
priate echo times [42-47]. The increased signal intensity
of the blood vessels due to the flow compensation may
enhance this signal cancelation leading to lower signal
intensities in voxels that contain both tissue and blood
vessels. However, the estimated very short T2* value
(~2 ms) of blood at the 30 min time point would virtu-
ally eliminate any signal from the blood and therefore
prevent any significant cancelation at this time point.
While some cancelation could occur at later time points,
the GEFC shows higher CNR at all time-points, which
makes signal cancelation unlikely to be the main cause
for the improved CNR. Likewise, measured SNR values
only showed a difference of about 10% between GE and
GEFC after correction due to the different receiver
bandwidths. The CNR changes observed were signifi-
cantly larger than 10% and cannot be wholly attributed
to a simple increase in the SNR of the GEFC scan.
It should be also noted, that magnetic susceptibility
difference between blood vessels and surrounding tissue
impacts signal of both GE and GEFC. For vessels that
are not parallel to the main magnetic field (B0), the sus-
ceptibility difference creates extravascular field inhomo-
geneities, thus strong T2
* decrease independent of the
blood flow. Considering isotropic distribution of tumor
vessels’ orientation and preferred direction introduced
by B0, a substantial fraction of the vessels is oriented at
angles larger than 50° with respect to the main magnetic
field [48]. The field inhomogeneities at larger angles
reach far beyond the actual vessel [47,49] thus the flow
compensation is more efficient enhancing contrast
due to the signal cancelation in the direction parallel ra-
ther than perpendicular to the main magnetic field
diminishing overall contrast improvement that would be
expected solely from the cancellation between blood and
surrounding tissue. As seen above there are various po-
tential mechanisms that may be responsible for the im-
proved CNR for GEFC when compared to GE. However
neither of these putative mechanisms can sufficiently ex-
plain the observed changes. While the above discussion
provides some explanation further studies into the origin
of these changes are warranted.
We presume that the decrease in CNR for both GE
and GEFC (with a post-injection time of 2 and 24 hrs)
but sustaining CNR above pre-injection levels, could be
due to preferential retention of superparamagnetic NPs
within the tumor compared to the normal brain tissue
due to selective immunoaffinity of the targeted contrast
agent. These observations are important not only for gli-
oma detection within an experimental setting, but are
also applicable for clinical diagnosis. The results of these
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suggest that the best CNR is provided by SWI(GEFC)
compared to SE and GE pulse sequences. It should be
however noted that GE based pulse sequences and hence
SWI are prone to artifacts, in areas such as auditory
canal or frontal lobes, due to their sensitivity to suscepti-
bility effects. Our results also demonstrate that molecu-
lar MR imaging using targeted contrast agents can
enhance the detection of a relatively small number of
glioma cells if an improved and optimal pulse sequence
is used. Of particular interest is also the fact that CNR is
higher just after injection and remains higher at 24 hrs
point for GEFC and thus SWI(GEFC). This is important
for imaging comparing non-targeted and targeted iron
based contrast agents. The first time point (~20-30 min)
is important as then non selective accumulation occurs.
At the last time point (~24 hrs) targeted contrast agent
accumulation can be observed as more NPs are expected
to selectively bind to the tumor unlike non-target NPs
that are washed out by that time. Thus the results could
also be used for improved differentiation between
targeted and non-targeted contrast agents at diagnostic-
ally important time points.
Conclusion
The appropriate use of SWI and flow compensated pulse
sequences needs to be considered in the ongoing devel-
opment of molecular imaging, particularly in vasculature
rich tissues.
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